Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
Clinical trial NCT05754502 · UNKNOWN
Trial details
- NCT number
- NCT05754502
- Sponsor
- Consorzio Oncotech
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-07-27
- Primary completion
- 2024-09-21
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.